Yu-Ching Chang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yu-Ching Chang has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Cheng-Hsuan Tsai
Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
4 shared publications - Yen-Hung Lin
National Taiwan University Hospital
4 shared publications - Bo-Ching Lee
National Taiwan University Hospital
3 shared publications - Chi-Sheng Hung
Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
3 shared publications - Chin-Chen Chang
Primary Aldosteronism Center at National Taiwan University Hospital, Taipei, Taiwan
3 shared publications - Jeff Shihchieh Chueh
Department of Urology, National Taiwan University Hospital, Taipei, Taiwan
3 shared publications
Latest Publications
- Open Access
Fibrosis-4 Index and Long-Term Cardiovascular Outcomes in Primary Aldosteronism
Background: The fibrosis-4 index (FIB-4) is a simple noninvasive marker originally developed to assess liver fibrosis risk. Accumulating evidence suggests that FIB-4 is associated with adverse cardiovascular outcomes, but its prognostic relevance in patients with primary aldosteronism (PA) remains unclear. Methods: In this retrospective multicenter cohort study, patients with PA were stratified into low, intermediate, and high FIB-4 groups using established cutoffs: 2.67. Outcomes included all-cause mortality, ischemic stroke, hemorrhagic stroke, acute myocardial infarction, and major adverse cardiovascular events (MACE). Multivariable Cox proportional hazards models were used to estimate hazard ratios (HRs) across FIB-4 categories. Results: Among 2,467 patients with PA, 1,215 (49.3%) had FIB-4 2.67. Patients with higher FIB-4 were older and had lower body mass index, worse renal function, lower potassium, and a higher comorbidity burden. During follow-up, all-cause mortality increased across FIB-4 categories, from 13.9% in the low FIB-4 group to 58.1% in the high FIB-4 group. After multivariable adjustment, FIB-4 >2.67 was associated with higher risks of all-cause mortality (adjusted HR, 1.98; 95% CI, 1.54–2.54) and MACE (adjusted HR, 1.78; 95% CI, 1.44–2.20), compared with FIB-4 <1.3. Adjusted linear regression analyses showed that higher FIB-4 was significantly associated with lower renin and higher aldosterone-to-renin ratio. Conclusions: In patients with PA, elevated FIB-4 identified a high-risk subgroup with increased all-cause mortality and MACE. FIB-4 may serve as a simple, noninvasive tool for prognostic stratification in patients with PA. Novelty and Relevance: What Is New?: In this retrospective multicenter cohort of patients with primary aldosteronism, elevated FIB-4 identified a high-risk subgroup with increased all-cause mortality and MACE. FIB-4 was associated with PA-related biochemical markers, including plasma renin activity and the aldosterone-to-renin ratio, suggesting a link between FIB-4 and renin suppression in PA. This is the first study to evaluate the prognostic significance of FIB-4 in patients with PA and to examine its relationship with PA-related biochemical features. What Is Relevant?: PA is clinically heterogeneous, and conventional biochemical markers may not fully capture the cumulative multisystem risk burden in high-risk patients. FIB-4 is a simple, noninvasive, and routinely available index that may complement current risk stratification in PA by integrating biochemical, hepatic-metabolic, renal, and comorbidity-related information. Clinical Implications?: Incorporating FIB-4 into PA assessment may help identify patients who warrant more comprehensive evaluation of cardiovascular, renal, hepatic, and metabolic risk. Elevated FIB-4 may support closer clinical follow-up and more intensive risk-factor optimization in high-risk patients with PA.
Open AccessFibrosis-4 Index and Long-Term Cardiovascular Outcomes in Primary Aldosteronism
Background: The fibrosis-4 index (FIB-4) is a simple noninvasive marker originally developed to assess liver fibrosis risk. Accumulating evidence suggests that FIB-4 is associated with adverse cardiovascular outcomes, but its prognostic relevance in patients with primary aldosteronism (PA) remains unclear. Methods: In this retrospective multicenter cohort study, patients with PA were stratified into low, intermediate, and high FIB-4 groups using established cutoffs: 2.67. Outcomes included all-cause mortality, ischemic stroke, hemorrhagic stroke, acute myocardial infarction, and major adverse cardiovascular events (MACE). Multivariable Cox proportional hazards models were used to estimate hazard ratios (HRs) across FIB-4 categories. Results: Among 2,467 patients with PA, 1,215 (49.3%) had FIB-4 2.67. Patients with higher FIB-4 were older and had lower body mass index, worse renal function, lower potassium, and a higher comorbidity burden. During follow-up, all-cause mortality increased across FIB-4 categories, from 13.9% in the low FIB-4 group to 58.1% in the high FIB-4 group. After multivariable adjustment, FIB-4 >2.67 was associated with higher risks of all-cause mortality (adjusted HR, 1.98; 95% CI, 1.54–2.54) and MACE (adjusted HR, 1.78; 95% CI, 1.44–2.20), compared with FIB-4 <1.3. Adjusted linear regression analyses showed that higher FIB-4 was significantly associated with lower renin and higher aldosterone-to-renin ratio. Conclusions: In patients with PA, elevated FIB-4 identified a high-risk subgroup with increased all-cause mortality and MACE. FIB-4 may serve as a simple, noninvasive tool for prognostic stratification in patients with PA. Novelty and Relevance: What Is New?: In this retrospective multicenter cohort of patients with primary aldosteronism, elevated FIB-4 identified a high-risk subgroup with increased all-cause mortality and MACE. FIB-4 was associated with PA-related biochemical markers, including plasma renin activity and the aldosterone-to-renin ratio, suggesting a link between FIB-4 and renin suppression in PA. This is the first study to evaluate the prognostic significance of FIB-4 in patients with PA and to examine its relationship with PA-related biochemical features. What Is Relevant?: PA is clinically heterogeneous, and conventional biochemical markers may not fully capture the cumulative multisystem risk burden in high-risk patients. FIB-4 is a simple, noninvasive, and routinely available index that may complement current risk stratification in PA by integrating biochemical, hepatic-metabolic, renal, and comorbidity-related information. Clinical Implications?: Incorporating FIB-4 into PA assessment may help identify patients who warrant more comprehensive evaluation of cardiovascular, renal, hepatic, and metabolic risk. Elevated FIB-4 may support closer clinical follow-up and more intensive risk-factor optimization in high-risk patients with PA.
- Open Access
- 29 June 2026
- Published by Elsevier in SSRN Electronic Journal
Progression of Cardio-Kidney-Metabolic Stages and Mortality Risk in Initially Healthy Adults
Background: The cardio-kidney-metabolic (CKM) framework has been proposed as an integrated staging system for cardiometabolic risk. However, whether progression across CKM stages confers incremental mortality risk among individuals initially free of CKM abnormalities remains unclear.Methods: We conducted a prospective cohort study including 58,317 adults classified as CKM stage 0 at baseline who underwent at least two standardized health examinations between 1997 and 2016. CKM stage was reassessed at the last examination and categorized as stage 0, 1, 2, or 3–4. Participants were followed from the last examination through December 31, 2022 for mortality outcomes.Results: During a median follow-up of 12.9 years, progression across CKM stages was associated with a stepwise increase in mortality risk. Compared with individuals who remained at CKM stage 0, adjusted hazard ratios (aHRs) for all-cause mortality were 1.15 (95% confidence interval [CI], 1.00–1.31) for stage 1, 1.19 (95% CI, 1.04–1.37) for stage 2, and 1.65 (95% CI, 1.29–2.12) for stage 3–4 (P for trend <0.001). A similar graded association was observed for cardiovascular mortality (P for trend <0.001), with the highest risk in stage 3–4 (aHR, 3.15; 95% CI, 1.73–5.74). Notably, progression to early CKM stages (stage 1–2) was associated with increased mortality risk.Conclusion: Among adults initially classified as metabolically healthy at baseline, progression across CKM stages is associated with a graded increase in all-cause and cardiovascular mortality. These findings support CKM stage transition as a dynamic marker of risk and highlight the importance of preventing early cardiometabolic deterioration.
- 29 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessProgression of Cardio-Kidney-Metabolic Stages and Mortality Risk in Initially Healthy Adults
Background: The cardio-kidney-metabolic (CKM) framework has been proposed as an integrated staging system for cardiometabolic risk. However, whether progression across CKM stages confers incremental mortality risk among individuals initially free of CKM abnormalities remains unclear.Methods: We conducted a prospective cohort study including 58,317 adults classified as CKM stage 0 at baseline who underwent at least two standardized health examinations between 1997 and 2016. CKM stage was reassessed at the last examination and categorized as stage 0, 1, 2, or 3–4. Participants were followed from the last examination through December 31, 2022 for mortality outcomes.Results: During a median follow-up of 12.9 years, progression across CKM stages was associated with a stepwise increase in mortality risk. Compared with individuals who remained at CKM stage 0, adjusted hazard ratios (aHRs) for all-cause mortality were 1.15 (95% confidence interval [CI], 1.00–1.31) for stage 1, 1.19 (95% CI, 1.04–1.37) for stage 2, and 1.65 (95% CI, 1.29–2.12) for stage 3–4 (P for trend <0.001). A similar graded association was observed for cardiovascular mortality (P for trend <0.001), with the highest risk in stage 3–4 (aHR, 3.15; 95% CI, 1.73–5.74). Notably, progression to early CKM stages (stage 1–2) was associated with increased mortality risk.Conclusion: Among adults initially classified as metabolically healthy at baseline, progression across CKM stages is associated with a graded increase in all-cause and cardiovascular mortality. These findings support CKM stage transition as a dynamic marker of risk and highlight the importance of preventing early cardiometabolic deterioration.
- Open Access
Recognition and Treatment of Primary Aldosteronism in the Updated Guideline Era
Background: Primary aldosteronism (PA) is increasingly recognized as a common cause of hypertension. The 2025 Endocrine Society guideline introduced a simplified diagnostic framework, but its real-world clinical implications remain unclear. Methods: We conducted a multicenter retrospective cohort study of hypertensive patients undergoing PA testing in Taiwan. PA was defined biochemically according to the 2025 Endocrine Society criteria. Multivariable logistic regression identified factors associated with PA diagnosis and aldosterone-targeted therapy. Among patients with suppressed renin (≤1 ng/mL/h), restricted cubic splines evaluated the adjusted association between renin and PA probability. Results: Among 18,766 patients undergoing PA testing, 6,760 (36.0%) met diagnostic criteria for PA. PA was associated with older age, female sex, lower potassium, resistant hypertension, and a higher antihypertensive medication burden. Among patients with suppressed renin, lower renin remained significantly associated with higher adjusted PA probability. However, only 39.0% of patients with PA received aldosterone-targeted therapy, including 28.2% who received mineralocorticoid receptor antagonist therapy within 6 months and 9.4% who underwent adrenalectomy during follow-up. Lower renin, higher aldosterone, lower potassium, and resistant hypertension were associated with aldosterone-targeted therapy, while younger patients with fewer comorbidities were more likely to undergo adrenalectomy. Conclusions: Using the updated diagnostic framework, PA was highly prevalent among hypertensive patients undergoing PA testing. Nevertheless, many patients who met these biochemical criteria did not receive aldosterone-targeted therapy in routine care. These findings highlight the potential treatment implications of broader PA recognition and support the development of practical pathways to guide MRA therapy, adrenalectomy referral, and individualized management.
Open AccessRecognition and Treatment of Primary Aldosteronism in the Updated Guideline Era
Background: Primary aldosteronism (PA) is increasingly recognized as a common cause of hypertension. The 2025 Endocrine Society guideline introduced a simplified diagnostic framework, but its real-world clinical implications remain unclear. Methods: We conducted a multicenter retrospective cohort study of hypertensive patients undergoing PA testing in Taiwan. PA was defined biochemically according to the 2025 Endocrine Society criteria. Multivariable logistic regression identified factors associated with PA diagnosis and aldosterone-targeted therapy. Among patients with suppressed renin (≤1 ng/mL/h), restricted cubic splines evaluated the adjusted association between renin and PA probability. Results: Among 18,766 patients undergoing PA testing, 6,760 (36.0%) met diagnostic criteria for PA. PA was associated with older age, female sex, lower potassium, resistant hypertension, and a higher antihypertensive medication burden. Among patients with suppressed renin, lower renin remained significantly associated with higher adjusted PA probability. However, only 39.0% of patients with PA received aldosterone-targeted therapy, including 28.2% who received mineralocorticoid receptor antagonist therapy within 6 months and 9.4% who underwent adrenalectomy during follow-up. Lower renin, higher aldosterone, lower potassium, and resistant hypertension were associated with aldosterone-targeted therapy, while younger patients with fewer comorbidities were more likely to undergo adrenalectomy. Conclusions: Using the updated diagnostic framework, PA was highly prevalent among hypertensive patients undergoing PA testing. Nevertheless, many patients who met these biochemical criteria did not receive aldosterone-targeted therapy in routine care. These findings highlight the potential treatment implications of broader PA recognition and support the development of practical pathways to guide MRA therapy, adrenalectomy referral, and individualized management.
- 1 May 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (5)
Sex Differences in Cardiac Remodeling and Dysfunction in Primary Aldosteronism
BACKGROUND: Sex differences influence cardiovascular risk assessment and management; however, their role in aldosterone-mediated cardiac remodeling in primary aldosteronism remains incompletely understood. METHODS: We conducted a retrospective study of 547 patients with primary aldosteronism, including 249 men and 298 women. Clinical and echocardiographic data were collected at baseline and 1 year following aldosterone-targeted therapies. RESULTS: The mean age was 53.8 years in men and 54.6 years in women. At baseline, men had a higher left ventricular mass index (LVMI), whereas women had a higher prevalence of left ventricular (LV) hypertrophy and worse diastolic function, as indicated by a higher ratio of early diastolic transmitral to mitral annular velocity (E/e′) and left atrial volume index. In multivariable analyses, plasma aldosterone concentration (PAC) was associated with baseline LVMI in both sexes. Associations between PAC and baseline diastolic indices, including E/e′ and left atrial volume index, were observed in men but not in women in sex-stratified models. However, formal interaction testing did not demonstrate significant sex-by- PAC interactions for left atrial volume index, E/e′, or LAVI. After 1 year of treatment, LVMI reduction was comparable between sexes. Improvement in E/e′ was significantly less pronounced in women. LAVI decreased significantly in men but not in women, although between-sex differences in change were not statistically significant. CONCLUSIONS: Sex-specific differences in cardiac remodeling and diastolic function were observed in patients with primary aldosteronism. Despite lower baseline LVMI, women exhibited a more adverse cardiac phenotype, with a higher prevalence of left ventricular hypertrophy and worse diastolic function. Following aldosterone-targeted therapies, structural regression was similar between sexes, whereas diastolic function improved to a lesser extent in women.
- 1 May 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (5)
Sex Differences in Cardiac Remodeling and Dysfunction in Primary Aldosteronism
BACKGROUND: Sex differences influence cardiovascular risk assessment and management; however, their role in aldosterone-mediated cardiac remodeling in primary aldosteronism remains incompletely understood. METHODS: We conducted a retrospective study of 547 patients with primary aldosteronism, including 249 men and 298 women. Clinical and echocardiographic data were collected at baseline and 1 year following aldosterone-targeted therapies. RESULTS: The mean age was 53.8 years in men and 54.6 years in women. At baseline, men had a higher left ventricular mass index (LVMI), whereas women had a higher prevalence of left ventricular (LV) hypertrophy and worse diastolic function, as indicated by a higher ratio of early diastolic transmitral to mitral annular velocity (E/e′) and left atrial volume index. In multivariable analyses, plasma aldosterone concentration (PAC) was associated with baseline LVMI in both sexes. Associations between PAC and baseline diastolic indices, including E/e′ and left atrial volume index, were observed in men but not in women in sex-stratified models. However, formal interaction testing did not demonstrate significant sex-by- PAC interactions for left atrial volume index, E/e′, or LAVI. After 1 year of treatment, LVMI reduction was comparable between sexes. Improvement in E/e′ was significantly less pronounced in women. LAVI decreased significantly in men but not in women, although between-sex differences in change were not statistically significant. CONCLUSIONS: Sex-specific differences in cardiac remodeling and diastolic function were observed in patients with primary aldosteronism. Despite lower baseline LVMI, women exhibited a more adverse cardiac phenotype, with a higher prevalence of left ventricular hypertrophy and worse diastolic function. Following aldosterone-targeted therapies, structural regression was similar between sexes, whereas diastolic function improved to a lesser extent in women.
- Open Access
- 2 March 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 124, S4-S9
Definition, prevalence, and economic impacts of hypertension on the elderly population
- 2 March 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 124, S4-S9
Open AccessDefinition, prevalence, and economic impacts of hypertension on the elderly population
- Open Access
- 26 January 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (3) , 261-267
Use of iodinated and gadolinium-based contrast media in patients with chronic kidney disease: Consensus statements from nephrologists, cardiologists, and radiologists at National Taiwan University Hospital
- 26 January 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (3) , 261-267
Open AccessUse of iodinated and gadolinium-based contrast media in patients with chronic kidney disease: Consensus statements from nephrologists, cardiologists, and radiologists at National Taiwan University Hospital
- Open Access
- 2 December 2024
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 124 (11) , 1077-1083
Colchicine to prevent cardiovascular death after an acute myocardial infarction
- 2 December 2024
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 124 (11) , 1077-1083
Open AccessColchicine to prevent cardiovascular death after an acute myocardial infarction
- 1 January 2012
- Published by Optica Publishing Group
- p. JTh4J.6
Determination of Dioxins at Ultratrace Levels by Femtosecond Multiphoton Ionization/Mass Spectrometry
Dioxins contained in the soil was measured by means of multiphoton ionization mass spectrometry using a femtosecond laser. By a combination with gas chromatography, congeners of dioxins were determined at femtogram levels.
- 1 January 2012
- Published by Optica Publishing Group
- p. JTh4J.6
Determination of Dioxins at Ultratrace Levels by Femtosecond Multiphoton Ionization/Mass Spectrometry
Dioxins contained in the soil was measured by means of multiphoton ionization mass spectrometry using a femtosecond laser. By a combination with gas chromatography, congeners of dioxins were determined at femtogram levels.